Weitzel, Julia
Welsner, Matthias
Taube, Christian
Ballmann, Manfred
Sutharsan, Sivagurunathan
Funding for this research was provided by:
Universitätsmedizin Rostock
Article History
Received: 29 January 2024
Accepted: 19 June 2024
First Online: 1 July 2024
Declarations
:
: SS has received personal fees or grants from Galapagos, Proteostasis Therapeutics, Celtaxsys, Vertex Pharmaceuticals, Boehringer Ingelheim, Corbus Pharmaceuticals, and Ionis Pharmaceuticals outside the submitted work. Matthias Welsner received personal fees from Vertex Pharmaceuticals, Chiesi, CSL Behring, and Grifols outside of the submitted work. All other authors have no competing interests to declare.
: SS has received personal fees or grants from Galapagos, Proteostasis Therapeutics, Celtaxsys, Vertex Pharmaceuticals, Boehringer Ingelheim, Corbus Pharmaceuticals, and Ionis Pharmaceuticals outside the submitted work. Matthias Welsner received personal fees from Vertex Pharmaceuticals, Chiesi, CSL Behring, and Grifols outside of the submitted work. All other authors have no competing interests to declare.
: The studies involving human participants were reviewed and approved by Ethik-Kommission, Universität Duisburg-Essen (no. 19-8797-BO). Written informed consent was obtained from participants and/or their legal guardian(s) for publication of case report or identifying information/images in an online open-access publication.
: Author contributions Study conception: SS, MB. Data acquisition and analysis: JW, SS, MB, MW. Data interpretation: SS, JW, MB, MW, CT. Writing the original manuscript: JW, SS. Revising the work for important intellectual content: JW, MB, SS, MW, CT. All authors contributed to the article and approved the submitted version.